美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

药明生物ADR

8.40

+0.01000.12%

成交量：2.15万

成交额：18.22万

市值：170.96亿

市盈率：39.07

高：8.60

开：8.29

低：8.29

收：8.39

52周最高：11.21

52周最低：4.12

股本：20.35亿

流通股本：17.74亿

量比：0.52

换手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):0.2150

每股收益(LYR):0.2253

净资产收益率：10.50%

总资产收益率：5.89%

市净率：2.69

市盈率(LYR):37.29

数据加载中...

总览公司新闻资讯公告

美国OTC市场药明生物ADR盘中异动股价大涨5.75%报8.28美元

药明生物入选恒生可持续发展企业基准指数

药明生物荣膺弗若斯特沙利文2025年"全球客户价值领导力奖"

美国OTC市场药明生物ADR盘中异动早盘急速拉升6.41%报9.63美元

美国OTC市场药明生物ADR盘中异动早盘大幅下挫5.38%报9.84美元

美国OTC市场药明生物ADR盘中异动股价大涨5.59%报10.58美元

药明生物重磅推出WuXia™ 4.0：定点整合细胞株开发平台 TrueSite TI™

药明生物连续五年入选富时社会责任指数系列

药明生物荣膺"年度最佳CDMO"等三项IMAPAC奖项

药明生物近期及净零排放目标获科学碳目标倡议（SBTi）认证

药明生物2025年上半年业绩加速增长

药明生物爱尔兰工厂通过EMA认证启动创新生物药商业化生产

行业领先：药明生物WuXiUP成功实现中试规模全自动化原液连续生产

药明生物ADR8月11日成交额为3.98万美元

药明生物推出HEK293稳定细胞株构建平台WuXia293 Stable，赋能复杂生物药分子研发与生产

药明生物ADR8月8日成交额为27.78万美元

药明生物ADR8月7日成交额为45.51万美元

美国OTC市场药明生物ADR盘中异动股价大跌5.26%

药明生物ADR8月6日成交额为21.33万美元

药明生物ADR8月5日成交额为11.74万美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/WXXWY/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"WXXWY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WXXWY\",,,,,undefined,":{"symbol":"WXXWY","market":"US","secType":"STK","nameCN":"药明生物ADR","latestPrice":8.4,"timestamp":1765314000000,"preClose":8.39,"halted":0,"volume":21452,"delay":15,"floatShares":1773747646,"shares":2035256538,"eps":0.214998,"marketStatus":"已收盘","change":0.01,"latestTime":"12-09 16:00:00 EST 延时","open":8.29,"high":8.6,"low":8.29,"amount":182164.3424,"amplitude":0.036949,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.214998,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765357200000},"marketStatusCode":5,"adr":0,"adrRate":2,"exchange":"PINK LIMITED","adjPreClose":8.39,"volumeRatio":0.522654},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WXXWY\",,,,,undefined,":{"symbol":"WXXWY","floatShares":1773747646,"roa":"5.89%","roe":"10.50%","lyrEps":0.225273,"volumeRatio":0.522654,"shares":2035256538,"dividePrice":0,"high":8.6,"amplitude":0.036949,"preClose":8.39,"low":8.29,"week52Low":4.12,"pbRate":"2.69","psRate":"6.02","week52High":11.21,"institutionHeld":0,"latestPrice":8.4,"eps":0.214998,"divideRate":0,"volume":21452,"delay":15,"ttmEps":0.214998,"open":8.29,"prevYearClose":4.4275,"prevWeekClose":8.4,"prevMonthClose":8.1,"prevQuarterClose":10.495,"fiveDayClose":8.01,"twentyDayClose":8.76,"sixtyDayClose":9.989},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/WXXWY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-03-26","symbol":"WXXWY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1711425600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2020-12-10","symbol":"WXXWY","defaultRemindTime":1607610600000,"type":"split","dateTimestamp":1607576400000,"forFactor":1,"toFactor":3,"ratio":0.33}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"WXXWY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"WXXWY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2593,"buy":0.5556,"hold":0.1852,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":27,"updateTime":1756098000000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"WXXWY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586403694","title":"美国OTC市场药明生物ADR盘中异动 股价大涨5.75%报8.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586403694","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586403694?lang=zh_cn&edition=fundamental","pubTime":"2025-11-24 22:46","pubTimestamp":1763995604,"startTime":"0","endTime":"0","summary":"北京时间2025年11月24日22时46分，美国OTC市场药明生物ADR股票出现异动，股价大幅拉升5.75%。截至发稿，该股报8.28美元/股，成交量1811股，换手率0.00%，振幅0.13%。美国OTC市场药明生物ADR股票所在的生物技术行业中，整体涨幅为0.54%。美国OTC市场药明生物ADR公司简介：无锡药明康德集团是一家生物药物的合同开发和制造组织，简称“CDMO”。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124224644a70e9087&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124224644a70e9087&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2577388339","title":"药明生物入选恒生可持续发展企业基准指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2577388339","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577388339?lang=zh_cn&edition=fundamental","pubTime":"2025-10-22 08:30","pubTimestamp":1761093000,"startTime":"0","endTime":"0","summary":"此前，药明生物已入选恒指ESG指数及恒生ESG 50指数。恒生可持续发展企业基准指数旨在评定拥有卓越ESG表现的上市公司，为可持续投资提供基准。药明生物首席执行官、ESG委员会主席陈智胜博士表示：\"入选恒生指数系列，是对我们在可持续发展道路上持续突破的重要认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4803088_ZH03088_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1880383366.USD","SG9999002562.SGD","BK4585","BK1610","LU0181495838.USD","LU0823426308.USD","LU0516423174.USD","LU0327786744.USD","LU0140636845.USD","02269","LU2210150020.SGD","LU0819121731.USD","BK4112","LU0359202008.SGD","LU0348735423.USD","LU0672654240.SGD","BK1576","LU2095319765.USD","LU0043850808.USD","LU2210149790.SGD","LU0456827905.SGD","LU0856984785.SGD","PSCI","LU0516422366.SGD","LU1242518857.USD","LU3063872942.SGD","BK1589","LU0516422440.USD","LU1691799644.USD","LU0417516902.SGD","LU0417516738.SGD","MSCI","LU0109391861.USD","LU1804176565.USD","LU0289961442.SGD","LU1242518931.SGD","IE00B0JY6N72.USD","LU0511384066.AUD","WXXWY","LU0051755006.USD","LU0979878070.USD","LU0320764599.SGD","LU0516422952.EUR","LU2039709279.SGD","LU0307460666.USD","LU0588546209.SGD","LU0516423091.SGD","BK1141","LU1720050803.USD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2577869263","title":"药明生物荣膺弗若斯特沙利文2025年\"全球客户价值领导力奖\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2577869263","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577869263?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 17:30","pubTimestamp":1760952600,"startTime":"0","endTime":"0","summary":"上海2025年10月20日 /美通社/ -- 全球领先的合同研究、开发和生产服务公司药明生物宣布，公司荣获弗若斯特沙利文颁发的2025年生物药CRDMO行业 \"全球客户价值领导力奖\"。该奖项表彰了药明生物通过技术创新、卓越运营及对客户需求的前瞻洞察，持续为客户创造卓越价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4801893_ZH01893_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0516423174.USD","LU1688375341.USD","EMA","LU0320764599.SGD","WXXWY","LU0327786744.USD","LU0140636845.USD","LU1794554557.SGD","LU0348735423.USD","BK4121","LU0052750758.USD","LU0979878070.USD","LU0708995583.HKD","LU1242518857.USD","LU0516422366.SGD","LU1720050803.USD","LU0588546209.SGD","LU0456827905.SGD","LU0516422440.USD","LU3063872942.SGD","LU0819121731.USD","LU1242518931.SGD","BK1589","BK4081","02269","LU0359201612.USD","BK1576","LU0516422952.EUR","LU0417516738.SGD","BK1610","LU0181495838.USD","LU0051755006.USD","LU0823426480.USD","BK1141","LU0039217434.USD","IE00B0JY6N72.USD","LU0043850808.USD","LU0823426308.USD","LU2039709279.SGD","BK1521","LU0516423091.SGD","LU0417516902.SGD","SG9999002463.SGD","LU0348825331.USD","LU0456846285.SGD","LU1880383366.USD","LU0326950275.SGD","LU0856984785.SGD","LU0359202008.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2575695253","title":"美国OTC市场药明生物ADR盘中异动 早盘急速拉升6.41%报9.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575695253","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575695253?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 22:36","pubTimestamp":1760366180,"startTime":"0","endTime":"0","summary":"北京时间2025年10月13日22时36分，美国OTC市场药明生物ADR股票出现波动，股价快速拉升6.41%。截至发稿，该股报9.63美元/股，成交量416股，换手率0.00%，振幅1.77%。美国OTC市场药明生物ADR股票所在的生物技术行业中，整体涨幅为0.31%。美国OTC市场药明生物ADR公司简介：无锡药明康德集团是一家生物药物的合同开发和制造组织，简称“CDMO”。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101322362094c6b615&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101322362094c6b615&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2574690437","title":"美国OTC市场药明生物ADR盘中异动 早盘大幅下挫5.38%报9.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574690437","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574690437?lang=zh_cn&edition=fundamental","pubTime":"2025-10-10 21:46","pubTimestamp":1760103988,"startTime":"0","endTime":"0","summary":"北京时间2025年10月10日21时46分，美国OTC市场药明生物ADR股票出现异动，股价急速下跌5.38%。截至发稿，该股报9.84美元/股，成交量4812股，换手率0.00%，振幅0.48%。美国OTC市场药明生物ADR股票所在的生物技术行业中，整体跌幅为0.28%。美国OTC市场药明生物ADR公司简介：无锡药明康德集团是一家生物药物的合同开发和制造组织，简称“CDMO”。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010214628a6b319bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010214628a6b319bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2571655463","title":"美国OTC市场药明生物ADR盘中异动 股价大涨5.59%报10.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2571655463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571655463?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 22:42","pubTimestamp":1759156922,"startTime":"0","endTime":"0","summary":"北京时间2025年09月29日22时42分，美国OTC市场药明生物ADR股票出现波动，股价大幅上涨5.59%。截至发稿，该股报10.58美元/股，成交量251股，换手率0.00%，振幅0.00%。美国OTC市场药明生物ADR股票所在的生物技术行业中，整体涨幅为1.81%。美国OTC市场药明生物ADR公司简介：无锡药明康德集团是一家生物药物的合同开发和制造组织，简称“CDMO”。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929224202a6a68537&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929224202a6a68537&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2570483004","title":"药明生物重磅推出WuXia™ 4.0：定点整合细胞株开发平台 TrueSite TI™","url":"https://stock-news.laohu8.com/highlight/detail?id=2570483004","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570483004?lang=zh_cn&edition=fundamental","pubTime":"2025-09-25 19:43","pubTimestamp":1758800580,"startTime":"0","endTime":"0","summary":"上海2025年9月25日 /美通社/ -- 全球领先的合同研究、开发和生产服务公司药明生物今日宣布推出行业领先的定点整合CHO细胞株开发平台TrueSite TI。关于WuXia细胞株构建系列平台 WuXia是药明生物开发的高产哺乳动物细胞株构建系列平台，产量最高可达11克/升。WuXia平台历经技术迭代，TrueSite TI是最新推出的WuXia4.0平台，通过行业领先的定点整合技术，显著增强细胞株表达量和稳定性，大幅提升细胞株开发效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4783196_ZH83196_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1141","LU0140636845.USD","BK1589","LU0572944931.SGD","BK4121","LU0359202008.SGD","LU1242518857.USD","LU0456827905.SGD","LU1688375341.USD","LU0516423091.SGD","LU0823426308.USD","LU0456846285.SGD","LU0417516738.SGD","SG9999002562.SGD","LU0417516902.SGD","LU1242518931.SGD","LU0348735423.USD","LU0516422366.SGD","LU1720050803.USD","SG9999002463.SGD","LU0979878070.USD","LU0307460666.USD","IE00B0JY6N72.USD","LU0348825331.USD","LU1880383366.USD","LU0359201612.USD","LU0516423174.USD","LU0327786744.USD","LU0326950275.SGD","LU1794554557.SGD","WXXWY","LU0516422952.EUR","LU0708995583.HKD","BK1610","LU2039709279.SGD","02269","LU0052750758.USD","LU0819121731.USD","LU0856984785.SGD","LU0823426480.USD","LU0320764599.SGD","LU0051755006.USD","LU0039217434.USD","LU0181495838.USD","LU0516422440.USD","BK1576","BK1521","LU0588546209.SGD","LU0043850808.USD"],"gpt_icon":0},{"id":"2569761760","title":"药明生物连续五年入选富时社会责任指数系列","url":"https://stock-news.laohu8.com/highlight/detail?id=2569761760","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569761760?lang=zh_cn&edition=fundamental","pubTime":"2025-09-23 12:00","pubTimestamp":1758600000,"startTime":"0","endTime":"0","summary":"上海2025年9月23日 /美通社/ --全球领先的合同研究、开发和生产服务公司药明生物宣布，公司凭借在可持续发展领域的卓越表现入选\"富时社会责任指数系列\"，公司已连续五年获得此项认可。药明生物首席执行官、ESG委员会主席陈智胜博士表示：\"我们十分荣幸再次入选富时社会责任指数系列，这项认可将激励我们坚定推进可持续发展战略。被纳入富时社会责任指数系列的企业均需满足一系列ESG相关标准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4780904_ZH80904_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0516422952.EUR","LU0109391861.USD","LU0456827905.SGD","LU0979878070.USD","LU1720050803.USD","LU0516422440.USD","LU1688375341.USD","02269","LU1242518857.USD","SG9999002562.SGD","LU0181495838.USD","LU0320764599.SGD","LU0043850808.USD","IE00BKPKM429.USD","LU2095319765.USD","LU0289960550.SGD","LU0175139822.USD","SG9999002463.SGD","LU1880383366.USD","BK1141","MSCI","LU0708995583.HKD","BK1610","WXXWY","LU0051755006.USD","PSCI","LU0348735423.USD","LU0359201612.USD","LU0456846285.SGD","BK1576","LU0039217434.USD","LU0289961442.SGD","LU0516422366.SGD","LU1267930730.SGD","BK4585","LU2039709279.SGD","LU2210149790.SGD","LU0823426308.USD","LU0417516902.SGD","BK4588","LU2265009873.SGD","IE00B0JY6N72.USD","LU0140636845.USD","LU0348825331.USD","LU0327786744.USD","BK4121","LU1794554557.SGD","LU0819121731.USD","LU0672654240.SGD","LU0708995401.HKD"],"gpt_icon":0},{"id":"2566714978","title":"药明生物荣膺\"年度最佳CDMO\"等三项IMAPAC奖项","url":"https://stock-news.laohu8.com/highlight/detail?id=2566714978","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566714978?lang=zh_cn&edition=fundamental","pubTime":"2025-09-12 09:30","pubTimestamp":1757640600,"startTime":"0","endTime":"0","summary":"自2017年以来，药明生物已多次在IMAPAC举办的各类奖项评选中获奖。药明生物首席执行官陈智胜博士表示：\"我们非常高兴药明生物再次获得IMAPAC颁发的多项大奖，充分体现了客户以及行业对我们所创造价值的认可。截至2025年6月底，药明生物帮助客户研发和生产的综合项目高达864个，其中包括24个商业化生产项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4771384_ZH71384_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0516423174.USD","LU0588546209.SGD","02269","BK1589","LU0456827905.SGD","LU0307460666.USD","BK1521","LU0856984785.SGD","LU1880383366.USD","LU0327786744.USD","LU0572944931.SGD","LU0823426308.USD","LU1242518857.USD","LU0140636845.USD","LU0359201612.USD","LU0320764599.SGD","LU0979878070.USD","LU0516423091.SGD","LU1688375341.USD","BK4121","LU0039217434.USD","LU0051755006.USD","LU0348825331.USD","LU0181495838.USD","BK4139","LU0052750758.USD","BK1610","LU0417516738.SGD","LU0417516902.SGD","LU0516422440.USD","LU0326950275.SGD","LU0516422952.EUR","LU2039709279.SGD","LU1794554557.SGD","LU0823426480.USD","SG9999002463.SGD","LU0708995583.HKD","CDMO","LU0516422366.SGD","BK1576","LU0359202008.SGD","LU0456846285.SGD","SG9999002562.SGD","WXXWY","LU0819121731.USD","LU1242518931.SGD","LU0348735423.USD","LU1720050803.USD","LU0043850808.USD","BK1141"],"gpt_icon":1},{"id":"2563052696","title":"药明生物近期及净零排放目标获科学碳目标倡议（SBTi）认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2563052696","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563052696?lang=zh_cn&edition=fundamental","pubTime":"2025-08-28 17:00","pubTimestamp":1756371600,"startTime":"0","endTime":"0","summary":"药明生物是行业内首批获SBTi近期及净零减排目标认证的企业之一。药明生物首席执行官、ESG委员会主席陈智胜博士表示：\"我们很开心公司的近期及净零温室气体目标已经顺利获得SBTi认证。药明生物SBTi目标矩阵 净零目标到2050年实现全价值链温室气体净零排放。关于SBTi 科学碳目标倡议 是一家企业气候行动组织，旨在帮助全球企业和金融机构在应对气候变化方面发挥应有作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4761029_ZH61029_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2039709279.SGD","BK1141","LU0511384066.AUD","LU1242518857.USD","LU0051755006.USD","LU0516423091.SGD","BK1589","LU0109391861.USD","LU0516422366.SGD","WXXWY","BK1576","BK4585","LU0823426480.USD","LU0819121731.USD","SG9999002463.SGD","LU0326950275.SGD","LU0856984785.SGD","LU0588546209.SGD","WRI","LU0289739343.SGD","IE00B0JY6N72.USD","LU0823426308.USD","LU2210150020.SGD","LU0043850808.USD","LU0516422440.USD","LU0516423174.USD","LU0708995401.HKD","LU1267930730.SGD","LU1688375341.USD","02269","LU0175139822.USD","LU0572944931.SGD","MSCI","BK1521","LU0320764599.SGD","LU0359201612.USD","LU0672654240.SGD","LU2265009873.SGD","LU0039217434.USD","LU0052750758.USD","PSCI","BK4121","LU0359202008.SGD","LU0516422952.EUR","LU1242518931.SGD","LU1794554557.SGD","LU2095319765.USD","LU0327786744.USD","BK1610","LU0708995583.HKD"],"gpt_icon":1},{"id":"2560319995","title":"药明生物2025年上半年业绩加速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2560319995","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560319995?lang=zh_cn&edition=fundamental","pubTime":"2025-08-19 20:01","pubTimestamp":1755604860,"startTime":"0","endTime":"0","summary":"研究业务  集团打造了多个业界领先的生物药发现技术平台，在2025年保持强劲增长。开发业务  2025年上半年，集团新增了86个综合开发项目，进一步巩固了其拥有业界最大复杂生物药产品线之一的领先地位。生产业务  截至2025年6月30日，集团支持了67个临床III期项目和24个商业化生产项目，并计划在2025年完成25个PPQ。此外，药明合联生产基地已实现机械完工，并预计在2025年底正式投入运营，在2026年初开始GMP生产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4754491_ZH54491_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0516423091.SGD","LU0516422952.EUR","LU0039217434.USD","LU0417516738.SGD","BK1576","SG9999002562.SGD","LU0327786744.USD","LU0588546209.SGD","LU0823426308.USD","LU0320764599.SGD","LU0516423174.USD","LU0456846285.SGD","IE00B0JY6N72.USD","ADC","BK4211","LU0456827905.SGD","LU0307460666.USD","LU0819121731.USD","LU1880383366.USD","LU2039709279.SGD","LU0417516902.SGD","BK1141","WBS","LU0181495838.USD","LU1242518857.USD","LU1242518931.SGD","LU0348825331.USD","LU0348735423.USD","BK4231","LU0516422440.USD","BK1610","02269","LU0043850808.USD","LU0979878070.USD","LU1794554557.SGD","LU0052750758.USD","BK1589","BK4121","EMA","LU0359201612.USD","LU0823426480.USD","SG9999002463.SGD","LU0708995583.HKD","LU0516422366.SGD","BK4081","BK1521","LU0140636845.USD","LU0326950275.SGD","WXXWY"],"gpt_icon":1},{"id":"2560133188","title":"药明生物爱尔兰工厂通过EMA认证 启动创新生物药商业化生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2560133188","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560133188?lang=zh_cn&edition=fundamental","pubTime":"2025-08-18 12:00","pubTimestamp":1755489600,"startTime":"0","endTime":"0","summary":"自2023年以来，药明生物多个生产基地已相继获得EMA和美国FDA批准，为该款产品提供商业化生产服务。爱尔兰基地实现商业化生产突破 此次获批也标志着药明生物爱尔兰基地商业化生产服务正式扬帆起航。出色质量体系屡获全球认可 截至2024年底，药明生物始终以100%的成功率顺利通过42次国际药品监管机构检查，累计获得97项生产许可证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4753183_ZH53183_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0588546209.SGD","LU0456827905.SGD","LU0043850808.USD","LU0348735423.USD","LU0326950275.SGD","LU0516422440.USD","LU1242518931.SGD","LU1720050803.USD","IE00B0JY6N72.USD","LU0979878070.USD","LU0417516738.SGD","EMA","LU1794554557.SGD","BK1576","LU0456846285.SGD","SG9999002463.SGD","02269","BK1610","LU0516422366.SGD","LU1242518857.USD","LU1688375341.USD","LU0140636845.USD","LU0516423091.SGD","LU0417516902.SGD","LU0856984785.SGD","LU0181495838.USD","LU0708995583.HKD","LU1880383366.USD","WXXWY","BK1521","LU0516423174.USD","SG9999002562.SGD","LU0359201612.USD","LU0516422952.EUR","LU0039217434.USD","LU0327786744.USD","BK1589","LU0348825331.USD","LU0051755006.USD","BK4121","LU0823426308.USD","LU0823426480.USD","BK4081","LU0572944931.SGD","LU0307460666.USD","BK1141","LU0320764599.SGD","LU0819121731.USD","LU0359202008.SGD","LU2039709279.SGD"],"gpt_icon":0},{"id":"2558442640","title":"行业领先：药明生物WuXiUP成功实现中试规模全自动化原液连续生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2558442640","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558442640?lang=zh_cn&edition=fundamental","pubTime":"2025-08-12 17:00","pubTimestamp":1754989200,"startTime":"0","endTime":"0","summary":"药明生物在成功实现WuXiUP中试规模全连续生产的基础上，通过引入膜层析、自动化控制等前沿技术，并对PAT技术进行迭代优化，进一步实现中试规模的全自动化原液连续生产。经升级的WuXiUP全自动化连续生产平台将在提升生产效率和产品质量方面发挥更大作用，赋能客户加速生物药从研发到商业化的全流程。WuXiUP全自动连续生产线通过全线集成自动化系统，可实现24/7小时不间断高效运转，大幅减少人工操作环节，降低产品质量风险，提升生产效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4749500_ZH49500_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0052750758.USD","LU1720050803.USD","LU0307460666.USD","LU0708995583.HKD","LU0516423091.SGD","LU0348825331.USD","LU0819121731.USD","LU0043850808.USD","WXXWY","LU0140636845.USD","BK1141","LU0979878070.USD","BK1589","LU2039709279.SGD","LU0516422440.USD","LU1880383366.USD","LU0327786744.USD","LU0516422952.EUR","LU0348735423.USD","LU1242518931.SGD","LU0359201612.USD","SG9999002562.SGD","BK1521","BK1610","LU0359202008.SGD","LU0181495838.USD","LU0456846285.SGD","LU0051755006.USD","LU0823426480.USD","LU0516422366.SGD","LU0320764599.SGD","LU0039217434.USD","LU1688375341.USD","LU0417516902.SGD","LU0456827905.SGD","LU0856984785.SGD","LU1242518857.USD","LU0823426308.USD","BK1576","LU0417516738.SGD","LU1794554557.SGD","SG9999002463.SGD","IE00B0JY6N72.USD","02269","LU0326950275.SGD","LU0588546209.SGD","LU0572944931.SGD","LU0516423174.USD","BK4121"],"gpt_icon":0},{"id":"2558643957","title":"药明生物ADR8月11日成交额为3.98万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558643957","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558643957?lang=zh_cn&edition=fundamental","pubTime":"2025-08-12 16:37","pubTimestamp":1754987871,"startTime":"0","endTime":"0","summary":"美东时间2025年8月11日，药明生物ADR成交额为3.98万美元，成交额较昨日减少85.67%，当日成交量为5280.00股。药明生物ADR于2025年8月11日涨0.8%，报7.56美元，该股过去5个交易日跌4.3%，年初至今涨70.65%，过去60日涨25.79%。它成立于 2010 年，隶属于药明康德，并于 2017 年在香港联交所上市。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812172909a483cece&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812172909a483cece&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["WXXWY","BK4121"],"gpt_icon":0},{"id":"2558695940","title":"药明生物推出HEK293稳定细胞株构建平台WuXia293 Stable，赋能复杂生物药分子研发与生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2558695940","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558695940?lang=zh_cn&edition=fundamental","pubTime":"2025-08-11 16:30","pubTimestamp":1754901000,"startTime":"0","endTime":"0","summary":"WuXia293Stable平台具备显著优势，可大幅提升蛋白表达量，实现人源糖基化，还能最大化地降低或避免复杂难表达分子中常见的蛋白质截短或断裂问题，从而显著提升产品质量。WuXia293Stable细胞株在长期传代培养期间，始终保持稳定的表达水平与产品质量，助力实现不同规模的临床和商业化生产。药明生物依托其专有的HEK 293 宿主细胞株成功开发了WuXia293Stable平台。WuXia293Stable的单克隆抗体分批补料表达量高达5.0克 / 升，同时产物纯度得到显著提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4748257_ZH48257_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1242518931.SGD","LU1688375341.USD","LU0823426480.USD","LU0417516738.SGD","LU1720050803.USD","LU0516423174.USD","LU0708995583.HKD","LU0456827905.SGD","LU0823426308.USD","LU0359202008.SGD","LU1880383366.USD","LU0348825331.USD","LU0572944931.SGD","LU0588546209.SGD","LU0417516902.SGD","BK4121","LU1794554557.SGD","IE00B0JY6N72.USD","LU0327786744.USD","LU0039217434.USD","SG9999002562.SGD","LU0043850808.USD","LU0856984785.SGD","BK1610","LU0052750758.USD","LU0051755006.USD","LU0326950275.SGD","BK1141","LU0516422366.SGD","LU0979878070.USD","WXXWY","02269","LU0516423091.SGD","LU0348735423.USD","LU0516422952.EUR","LU1242518857.USD","LU0307460666.USD","BK1589","LU2039709279.SGD","BK1521","LU0181495838.USD","LU0516422440.USD","LU0320764599.SGD","LU0456846285.SGD","LU0140636845.USD","LU0819121731.USD","BK1576","SG9999002463.SGD","LU0359201612.USD"],"gpt_icon":0},{"id":"2558219509","title":"药明生物ADR8月8日成交额为27.78万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558219509","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558219509?lang=zh_cn&edition=fundamental","pubTime":"2025-08-09 16:36","pubTimestamp":1754728576,"startTime":"0","endTime":"0","summary":"美东时间2025年8月8日，药明生物ADR成交额为27.78万美元，成交额较昨日减少38.96%，当日成交量为3.71万股。药明生物ADR于2025年8月8日跌2.22%，报7.5美元，该股过去5个交易日跌4.21%，年初至今涨69.3%，过去60日涨27.12%。它成立于 2010 年，隶属于药明康德，并于 2017 年在香港联交所上市。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809163621a6dc4f9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809163621a6dc4f9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2557523564","title":"药明生物ADR8月7日成交额为45.51万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557523564","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557523564?lang=zh_cn&edition=fundamental","pubTime":"2025-08-08 16:31","pubTimestamp":1754641891,"startTime":"0","endTime":"0","summary":"美东时间2025年8月7日，药明生物ADR成交额为45.51万美元，成交额较昨日增加113.37%，当日成交量为5.91万股。药明生物ADR于2025年8月7日跌4.01%，报7.67美元，该股过去5个交易日跌6.12%，年初至今涨73.14%，过去60日涨28.05%。它成立于 2010 年，隶属于药明康德，并于 2017 年在香港联交所上市。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808180511a47d074e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808180511a47d074e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2557313562","title":"美国OTC市场药明生物ADR盘中异动 股价大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557313562","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557313562?lang=zh_cn&edition=fundamental","pubTime":"2025-08-07 22:39","pubTimestamp":1754577581,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日22时39分，美国OTC市场药明生物ADR股票出现波动，股价急速下挫5.26%。美国OTC市场药明生物ADR股票所在的生物技术行业中，整体跌幅为0.17%。美国OTC市场药明生物ADR公司简介：无锡药明康德集团是一家生物药物的合同开发和制造组织，简称“CDMO”。它成立于 2010 年，隶属于药明康德，并于 2017 年在香港联交所上市。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080722394194d5bb0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080722394194d5bb0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2557563915","title":"药明生物ADR8月6日成交额为21.33万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557563915","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557563915?lang=zh_cn&edition=fundamental","pubTime":"2025-08-07 16:23","pubTimestamp":1754555032,"startTime":"0","endTime":"0","summary":"美东时间2025年8月6日，药明生物ADR成交额为21.33万美元，成交额较昨日增加81.62%，当日成交量为2.67万股。药明生物ADR于2025年8月6日跌0.5%，报7.99美元，该股过去5个交易日跌2.92%，年初至今涨80.36%，过去60日涨36.58%。它成立于 2010 年，隶属于药明康德，并于 2017 年在香港联交所上市。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807173053a47aa04b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807173053a47aa04b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2557324838","title":"药明生物ADR8月5日成交额为11.74万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557324838","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557324838?lang=zh_cn&edition=fundamental","pubTime":"2025-08-06 16:14","pubTimestamp":1754468064,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日，药明生物ADR成交额为11.74万美元，成交额较昨日增加12.57%，当日成交量为1.45万股。药明生物ADR于2025年8月5日涨1.65%，报8.03美元，该股过去5个交易日跌4.63%，年初至今涨81.26%，过去60日涨39.65%。它成立于 2010 年，隶属于药明康德，并于 2017 年在香港联交所上市。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806165519a6d63313&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806165519a6d63313&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":49,"code":"91000000","status":"200"}]}}